Chengdu Ailin Biotechnology

Chengdu Ailin Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative small molecule drugs. The company leverages its proprietary Ailin-PPI platform, which focuses on targeting protein-protein interactions and other challenging "undruggable" targets through structure-based drug design. Its lead program, AL-001, is a potent SHP2 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Ailin's pipeline also includes inhibitors targeting SOS1, KRAS, and USP1, primarily focusing on oncology and precision medicine. The company aims to provide breakthrough therapies for patients with high unmet medical needs in the cancer field.